Gannex/Ascletis Reports Positive Phase II Data for NASH Treatment
March 09, 2021 at 04:14 AM EST
Shanghai Gannex Pharma, a subsidiary of Hangzhou 's Ascletis, reported positive topline results from the China cohort of a Phase II trial for its nonalcoholic steatohepatitis (NASH) treatment. The randomized, placebo-controlled trial tested ASC40, a novel oral, once-daily fatty acid synthase (FASN) inhibitor, developed by Sagimet Biosciences of San Mateo, CA. In 2019, Ascletis led a $25 million Series E financing of Sagimet in return for China rights to the candidate. More details.... Stock Symbol: (HK:1672) Share this with colleagues: // //